Contineum Therapeutics (CTNM) EBITDA (2023 - 2024)
Historic EBITDA for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to -$15.1 million.
- Contineum Therapeutics' EBITDA fell 9882.46% to -$15.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 28466.21%. This contributed to the annual value of -$42.3 million for FY2024, which is 28466.21% down from last year.
- As of Q4 2024, Contineum Therapeutics' EBITDA stood at -$15.1 million, which was down 9882.46% from -$9.6 million recorded in Q3 2024.
- Over the past 5 years, Contineum Therapeutics' EBITDA peaked at $41.5 million during Q2 2023, and registered a low of -$15.1 million during Q4 2024.